Clinical trials: Neoadjuvant Immunochemotherapy
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China, with most patients presenting with locally advanced disease.
- Trial name
- TTE-ESCC (NCT07778056)
- Testing
- Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell…
- Trial name
- HCHTOG2603 (NCT07629817)
- Testing
- Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world.
- Trial name
- NeoR-World (NCT05974007)
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study is a prospective, multicenter, open-label, observational cohort study. The primary endpoint is pathological complete response (pCR), and the secondary endpoints include R0 resection rate, ctDNA clearance rate, major…
- Trial name
- ctDNA (NCT06103890)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.
- Trial name
- NCT07182565
- Testing
- hypofractionated radiotherapy, PD-1 inhibitor, TS-1
- Where
- 4 sites in China
- Volunteers
- 84 people
- Sponsor
- West China Hospital
Non Small Cell Lung Cancer, Immunotherapy
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date.
- Conditions
- Non Small Cell Lung Cancer, Immunotherapy, Chemotherapy, Tumour, Residual
- Trial name
- NCT05637580
- Testing
- Timing of drug administration
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Guangdong Provincial People's Hospital
Esophageal Squamous Cell Carcinoma
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06446726
- Testing
- Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma (ESCC)
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe.
- Trial name
- NCT07822906
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Toripalimab, Surufatinib
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable…
- Conditions
- Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, Chemoradiotherapy
- Trial name
- NCT07086469
- Testing
- Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Non-small Cell Lung Cancer
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell…
- Trial name
- neoSCORE Ⅱ (NCT05429463)
- Testing
- Sintilimab, Carboplatin, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Non-Small-Cell Lung
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for operable stage II to III non-small…
- Trial name
- SACTION01 (NCT05319574)
- Testing
- SBRT, Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Cervical Cancers
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of paclitaxel and carboplatin combined with PD-1/PD-L1 immune checkpoint inhibitors in the treatment of locally advanced…
- Trial name
- NCT07003620
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
- Trial name
- NCT07145931
- Testing
- Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
SBRT, Neoadjuvant Immunochemotherapy
Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study
Neoadjuvant immunotherapy before surgery has shown good efficacy and safety in locally advanced HNSCC, particularly with the use of PD-1 inhibitors combined with chemotherapy, where some patients have achieved a high rate of…
- Conditions
- SBRT, Neoadjuvant Immunochemotherapy, LA HNSCC
- Trial name
- NCT06722495
- Testing
- SBRT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Muscle-Invasive Bladder Carcinoma
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC).
- Trial name
- NCT04506554
- Testing
- AMVAC + Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Fox Chase Cancer Center
Esophageal Cancer
The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer
Treatment with immune checkpoint inhibitors such as programmed death receptor 1 (PD-1 inhibitors) for advanced and metastatic esophageal squamous cell carcinoma (ESCC) significantly improves patients' overall survival compared to…
- Trial name
- POSITRON (NCT05615103)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Lung Cancer (NSCLC)
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
The goal of this clinical trial is to compare the efficacy and safety of neoadjuvant Stereotactic Body Radiotherapy (SBRT) combined with immunochemotherapy versus neoadjuvant immunochemotherapy.
- Trial name
- SACTION2401 (NCT06598527)
- Testing
- Stereotactic body radiotherapy (SBRT), Tislelizumab, Chemotherapy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Yang Hong
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University